Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

Phase 2 Completed 40 enrolled HonorHealth Research Institute

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with resectable and unresectable pancreatic cancer.

Timeline

Start: 2017-05-23
Primary completion: 2023-07-13
Completion: 2025-11-03

Publications

Viniotis AF, Jameson GS, Wertheim BC, Roe DJ, Lee K, Tsai FY, Gordon MS, Sharma S, Guarnieri CM, Snyder CE, Thosani AJ, Amini A, Sckolnik SE, Garrick JM, Korn RL, Rahmanuddin S, Evans RM, Downes M, Truitt M, Von Hoff DD, Borazanci EH. A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer. Oncologist. 2026 Jun 6;31(7):oyag232. doi: 10.1093/oncolo/oyag232.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	25 mg/m2	Intravenous
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	125 mg/m2	Intravenous
Subject	Paricalcitol	Other / unclassified	25 ug	—

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

Summary

Timeline

Publications

Drugs

Indications